Dechra Pharmaceuticals (DB:1PK) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

1PK Panoramica delle azioni

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians.

Informazioni sull'azienda

1PK analisi fondamentale
Punteggio fiocco di neve
Valutazione	0/6
Crescita futura	4/6
Prestazioni passate	0/6
Salute finanziaria	1/6
Dividendi	0/6

Premi

Si prevede che gli utili cresceranno del 62.48% all'anno

Analisi del rischio

I pagamenti degli interessi non sono ben coperti dagli utili

Dechra Pharmaceuticals PLC Concorrenti

Dermapharm Holding

XTRA:DMP

€1.9b

Bayer

XTRA:BAYN

€29.9b

Merck KGaA

XTRA:MRK

€69.8b

Alimera Sciences

DB:ASZ1

€257.0m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Dechra Pharmaceuticals
Prezzi storici delle azioni
Prezzo attuale dell'azione	UK£44.40
Massimo di 52 settimane	UK£45.20
Minimo di 52 settimane	UK£28.00
Beta	0.78
1Variazione di 1 mese	0.45%
Variazione a 3 mesi	2.30%
Variazione di 1 anno	35.37%
3Variazione a 3 anni	9.25%
Variazione a 5 anni	65.18%
Variazione dall'IPO	272.64%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	1PK	DE Pharmaceuticals	DE Mercato
7D	-0.4%	3.1%	4.5%
1Y	35.4%	-12.1%	13.4%

Ritorno vs Industria: 1PK ha superato il German Pharmaceuticals che ha restituito -13.5 % nell'ultimo anno.

Rendimento vs Mercato: 1PK ha superato il mercato German che ha restituito 4.7 % nell'ultimo anno.

Volatilità dei prezzi

Is 1PK's price volatile compared to industry and market?
1PK volatility
1PK Average Weekly Movement	2.8%
Pharmaceuticals Industry Average Movement	5.2%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	11.8%
10% least volatile stocks in DE Market	2.4%

Prezzo delle azioni stabile: 1PK non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 3% ) di 1PK è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1997	2,457	Ian Page	www.dechra.com

Dechra Pharmaceuticals PLC Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Dechra Pharmaceuticals con la sua capitalizzazione di mercato?
1PK statistiche fondamentali
Capitalizzazione di mercato	€5.11b
Guadagni(TTM)	-€32.39m
Ricavi(TTM)	€884.12m

5.8x

Rapporto P/S

-157.8x

Rapporto P/E

1PK è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
1PK Conto economico (TTM)
Ricavi	UK£761.50m
Costo del fatturato	UK£331.90m
Profitto lordo	UK£429.60m
Altre spese	UK£457.50m
Guadagni	-UK£27.90m

Ultimi guadagni dichiarati

Jun 30, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-0.24
Margine lordo	56.42%
Margine di profitto netto	-3.66%
Rapporto debito/patrimonio netto	64.6%

Come si è comportato 1PK nel lungo periodo?

Vedi performance storica e confronto

1PK Panoramica delle azioni

Premi

Analisi del rischio

Dechra Pharmaceuticals PLC Concorrenti

XTRA:DMP

€1.9b

XTRA:BAYN

€29.9b

XTRA:MRK

€69.8b

DB:ASZ1

€257.0m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Recent updates

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Dechra Pharmaceuticals' Cancellation of Listing and Admission to Trading of Shares Expected on 17 January 2024

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals PLC to Report Fiscal Year 2023 Results on Oct 12, 2023

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Dechra Pharmaceuticals plc Announces Resignation of Ishbel Macpherson as Non-Executive Director

Dechra Pharmaceuticals Intends to Delist from Official List

Investor sentiment improves as stock rises 33%

First half 2023 earnings released: EPS: UK£0.20 (vs UK£0.38 in 1H 2022)

Investor sentiment improved over the past week

Dechra Pharmaceuticals PLC Appoints Geeta Gopalan as A Non-Executive Director of the Company

Now 20% undervalued after recent price drop

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 100 Index

Less than half of directors are independent

Upcoming dividend of UK£0.33 per share

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 19, 2023

Full year 2022 earnings released: EPS: UK£0.54 (vs UK£0.51 in FY 2021)

Dechra Pharmaceuticals plc Proposes Final Dividend for the Year Ended June 30, 2022

Dechra Pharmaceuticals PLC (LSE:DPH) acquired Med-Pharmex, Inc. from DW Management Services, LLC for $260 million on a debt-free and cash-free basis.

Dechra Pharmaceuticals PLC (LSE : DPH) agreed to acquire Piedmont Animal Health LLC for approximately $210 million.

Now 22% undervalued after recent price drop

Dechra Pharmaceuticals PLC Announces Executive Changes

Now 21% undervalued after recent price drop

Less than half of directors are independent

Non-Executive Chairman recently bought €119k worth of stock

Upcoming dividend of UK£0.12 per share

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Dechra Pharmaceuticals PLC Declares Interim Dividend, Payable on April 7, 2022

Dechra Pharmaceuticals plc Announces Executive Changes

Dechra Pharmaceuticals PLC (LSE:DPH) agreed to acquire Worldwide Rights to Verdinexor from Anivive Lifesciences, Inc.

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Non-Executive Director Denise Goode has left the company

Upcoming dividend of UK£0.29 per share

Upcoming dividend of UK£0.29 per share

Board Member recently sold €1.0m worth of stock

Full year 2021 earnings released: EPS UK£0.51 (vs UK£0.33 in FY 2020)

Board Member recently sold €1.1m worth of stock

First half 2021 earnings released: EPS UK£0.22 (vs UK£0.13 in 1H 2020)

Akston Biosciences Signs Licensing Agreement with Dechra Pharma for Aks-425C

New 90-day high: €41.36

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 21, 2021

New 90-day high: €38.84

CEO, MD & Executive Director recently sold €12m worth of stock

Dechra Pharmaceuticals PLC Launches Mirataz

Upcoming Dividend of UK£0.24 Per Share

Dechra Pharmaceuticals PLC to Report First Half, 2021 Results on Feb 22, 2021

New 90-day high: €38.52

Non-Executive Director recently bought €28k worth of stock

Non-Executive Director recently bought €28k worth of stock

Independent Non Executive Director recently sold €142k worth of stock

Full year earnings released - EPS €0.33

New 90-day high - €36.48

New 90-day high - €33.70